Cargando…

Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow

The underlying mechanisms behind the effect of atorvastatin on patients with coronary slow flow (CSF) remain largely unknown. To investigate the possible underlying molecular mechanisms 108 patients were divided into atorvastatin group and control group. Coronary flow was quantified according to cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Hongmei, Wei, Zhenzhen, Zhang, Yanling, He, Jian, Jia, Danyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772870/
https://www.ncbi.nlm.nih.gov/pubmed/29399097
http://dx.doi.org/10.3892/etm.2017.5484
_version_ 1783293476186619904
author Niu, Hongmei
Wei, Zhenzhen
Zhang, Yanling
He, Jian
Jia, Danyan
author_facet Niu, Hongmei
Wei, Zhenzhen
Zhang, Yanling
He, Jian
Jia, Danyan
author_sort Niu, Hongmei
collection PubMed
description The underlying mechanisms behind the effect of atorvastatin on patients with coronary slow flow (CSF) remain largely unknown. To investigate the possible underlying molecular mechanisms 108 patients were divided into atorvastatin group and control group. Coronary flow was quantified according to corrected TIMI frame count (CTFC). Serum high sensitivity C-reactive protein (hs-CRP), lipids, ET-1, interleukin (IL)-6, NO, circulating endothelial progenitor cell (cEPC) count, adhesion, migration and proliferation were measured in pretreatment and post-treatment. After respective treatment, the atorvastatin group had significantly decreased levels of TC, TG, LDL-C, hs-CRP, ET-1 and IL-6 and increased NO compared to the control group. The atorvastatin group had a more significant improvement of CTFC, effective rate, cEPC number, EPC adhesion, migration and proliferation compared to the control group. In conclusion, atorvastatin can be used in treatment of CSF by suppressing inflammation and improving endothelial function.
format Online
Article
Text
id pubmed-5772870
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-57728702018-02-02 Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow Niu, Hongmei Wei, Zhenzhen Zhang, Yanling He, Jian Jia, Danyan Exp Ther Med Articles The underlying mechanisms behind the effect of atorvastatin on patients with coronary slow flow (CSF) remain largely unknown. To investigate the possible underlying molecular mechanisms 108 patients were divided into atorvastatin group and control group. Coronary flow was quantified according to corrected TIMI frame count (CTFC). Serum high sensitivity C-reactive protein (hs-CRP), lipids, ET-1, interleukin (IL)-6, NO, circulating endothelial progenitor cell (cEPC) count, adhesion, migration and proliferation were measured in pretreatment and post-treatment. After respective treatment, the atorvastatin group had significantly decreased levels of TC, TG, LDL-C, hs-CRP, ET-1 and IL-6 and increased NO compared to the control group. The atorvastatin group had a more significant improvement of CTFC, effective rate, cEPC number, EPC adhesion, migration and proliferation compared to the control group. In conclusion, atorvastatin can be used in treatment of CSF by suppressing inflammation and improving endothelial function. D.A. Spandidos 2018-01 2017-11-10 /pmc/articles/PMC5772870/ /pubmed/29399097 http://dx.doi.org/10.3892/etm.2017.5484 Text en Copyright: © Niu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Niu, Hongmei
Wei, Zhenzhen
Zhang, Yanling
He, Jian
Jia, Danyan
Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow
title Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow
title_full Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow
title_fullStr Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow
title_full_unstemmed Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow
title_short Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow
title_sort atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772870/
https://www.ncbi.nlm.nih.gov/pubmed/29399097
http://dx.doi.org/10.3892/etm.2017.5484
work_keys_str_mv AT niuhongmei atorvastatinimprovescoronaryflowandendothelialfunctioninpatientswithcoronaryslowflow
AT weizhenzhen atorvastatinimprovescoronaryflowandendothelialfunctioninpatientswithcoronaryslowflow
AT zhangyanling atorvastatinimprovescoronaryflowandendothelialfunctioninpatientswithcoronaryslowflow
AT hejian atorvastatinimprovescoronaryflowandendothelialfunctioninpatientswithcoronaryslowflow
AT jiadanyan atorvastatinimprovescoronaryflowandendothelialfunctioninpatientswithcoronaryslowflow